This suggests that SGLT2 inhibitors prevent hepatic steatosis not only via its insulin-independent glucose-lowering effect and caloric loss but also via modulating energy homeostasis and balance in adipose and non-adipose tissues. This evidence concerns the gene INS and Hepatic steatosis.